Influenza is a condition that causes contagious illness. It is characterized by sudden onset of fever, headache, sore throat, non-productive cough, and rhinitis. Usually infection lasts for about a week. Over the course of a flu season, different types and subtypes of influenza can cause illness in humans. There are four types of influenza virus such as A, B, C, and D. Influenza A and B virus causes most of the illness in humans. Prolonged influenza infections can cause severe complications such as pneumonia, bronchitis, acute respiratory distress, secondary bacterial infections, and cardiovascular complications. To control the illness caused by influenza virus, influenza antiviral prescription drugs can be used. Click To Read More On Influenza Therapeutics Market
New drug approvals for the treatment of influenza is expected to drive the influenza therapeutics market growth. For instance, in October 2018, Roche announced that the U.S. Food and Drug Administration (FDA) approved Xofluza (TM) (baloxavir marboxil) for the treatment of acute, uncomplicated influenza or flu, in people 12 years of age and older.
Increasing number of clinical pipeline studies is expected to boost the influenza therapeutics market growth during the forecast period. For instance, in January 2018, Romark Laboratories L.C. initiated the phase 3 clinical trial for Nitazoxanide to evaluate its efficacy and safety in the treatment of uncomplicated influenza. Nitazoxanide is a broad-spectrum antiparasitic and broad-spectrum antiviral drug, used in the treatment of intestinal parasitic infections caused by Cryptosporidium parvam and Giardia lamblia. This study is expected to be completed in April 2019.
Influenza Therapeutics Market: Regional Analysis
On the basis of region, the global influenza therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America holds dominant position in the market, owing to high presence of key players such as GlaxoSmithKline plc and Hoffmann-La Roche Ltd. The regulatory agencies in the region select influenza viruses that are required for developing the influenza vaccine.
Get The Free PDF Sample Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2443
Asia Pacific is also expected to witness significant growth in the influenza therapeutics market, owing to increasing initiatives by the Asia-Pacific Alliance for the Control of Influenza (APACI), to reduce the burden of influenza by enhancing control measures and boosting pandemic preparedness in the region, through the provision of educational information and activities.
Key players operating in the global influenza therapeutic market include Daiichi Sankyo Company, GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Sun Pharmaceutical Industries Ltd., BiondVax Pharmaceuticals Ltd., Atriva Therapeutics Gmbh, Texas Medical Center, Life Science Austria (LISA), GE Healthcare Life Sciences, Sanofi Pasteur SA and Mylan, Inc.